How much does Central Pharma Cell and Gene Therapy Ltd make?

Central Pharma Cell and Gene Therapy Ltd reported revenue of £513k and a loss of £292k in the year to 31 Dec 2024, according to its accounts filed at Companies House.

How many employees does Central Pharma Cell and Gene Therapy Ltd have?

Central Pharma Cell and Gene Therapy Ltd reported an average of 3 employees in the year to 31 Dec 2024.

Is Central Pharma Cell and Gene Therapy Ltd profitable?

No — Central Pharma Cell and Gene Therapy Ltd reported a loss of £292k in the year to 31 Dec 2024.

Company No. 12769240 · Incorporated 27 Jul 2020

Central Pharma Cell and Gene Therapy Ltd

Registered name: CENTRAL PHARMA CELL AND GENE THERAPY LTD

Part of Central Pharma Contract Holdings Limited group

Central Pharma Cell and Gene Therapy Ltd made £513k revenue and a £292k loss in the year to 31 Dec 2024.

Central Pharma Cell and Gene Therapy Ltd’s revenue fell 31% to £513k in the year to 31 Dec 2024, with a loss of £292k and 3 employees. The company is classified under “other professional, scientific and technical activities” and is based in Bedford; we hold 3 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 74909Other professional, scientific and technical activities n.e.c.SIC 82920Packaging activities

Status: Active
Location: Bedford, South East
Age: 6 yrs · since 2020
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2024

Key figures

Small teamCapital-light

Revenue

£513k

Growth ▼30.8%

Profit

−£292k

Growth ▼21264%

Profit margin

−56.9%

Gross 91%

Employees

Change 0%

Profit / employee

−£97.2k

Revenue/employee £171k

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

3 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Dec 2022	31 Dec 2023	31 Dec 2024
Disclosure	No P&L	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	—	£741k	£513k
Cost of sales	—	£47.8k	£45.9k
Gross profit	—	£694k	£467k
Operating profit	—	£14.4k	−£291k
Profit before tax	—	£1.4k	−£292k
Profit after tax	—	£1.4k	−£292k
Profit (best available)	—	£1.4k	−£292k
Employees (average)	5	3	3
Ratios
Profit margin	—	0.2%	−56.9%
Gross margin	—	93.6%	91%
Revenue per employee	—	£247k	£171k
Profit per employee	—	£459	−£97.2k
Growth (year on year)
Revenue growth	—	—	▼30.8%
Profit growth	—	—	▼21264%
Headcount growth	—	▼40%	0%
Balance sheet — indirect signals, not revenue
Cash at bank	£9.9k	£62.3k	£3.5k
Net assets	−£1.9m	−£1.9m	−£2.2m
Fixed assets	£44.5k	£39.5k	£23.8k
Current assets	£60.3k	£252k	£126k
Debtors	£0	£161k	£39.1k
Source	FullAccounts · bulk data Nov 2024	FullAccounts · bulk data Nov 2024	FullAccounts · bulk data Sep 2025

Derived from the latest filing

How the business works

Profit margin: −56.9%; Profit ÷ revenue.
Gross margin: 91%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £171k; Revenue ÷ average employees.
Profit per employee: −£97.2k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 4.6%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: —; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 7.6%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now −£2.2m
Cash at bank: ▼94%; Now £3.5k
Headcount: 0%; Now 3
Deferred income: —; Now —
Fixed assets: ▼40%; Now £23.8k

Corporate ownership

Group structure

Ownership chain

Central Pharma Contract Holdings Limitedultimate parent75–100%
Central Pharma Cell and Gene Therapy Ltdthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (3)

Central Pharma Contract Packing LimitedRev. £17.9m · Profit £237k
Central Pharma Biotechnica LimitedRev. £563k · Profit −£307k
Central Pharma Manufacturing LtdFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Dec 2024 (profit −£292k), from the Companies House accounts bulk data published Sep 2025. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.